NCT07470489 2026-04-16
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
50 trialsNCT07485569 2026-04-15
REPOTHYROID-II
Radboud University Medical Center
Phase 1 Not yet recruiting
NCT05696548 2026-04-09
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT03975231 2026-04-08
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT07068542 2026-02-24
TROPION
Zhejiang Provincial People's Hospital
Phase NA Recruiting
NCT04675710 2026-02-19
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04171622 2026-02-17
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06639191 2026-01-30
AKIR001
Karolinska University Hospital
Phase EARLY_PHASE1 Recruiting
NCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT03449108 2025-11-21
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04759911 2025-11-13
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06902376 2025-11-05
NEO-COMBATXL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT05453799 2025-10-20
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
Northwestern University
Phase 2 Active not recruiting
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT06374602 2025-09-05
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia
Phase 2 Recruiting
NCT07138261 2025-08-22
TATC
National Health Research Institutes, Taiwan
Not yet recruiting
NCT03085056 2025-07-03
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04238624 2025-07-02
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT04552769 2025-06-05
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT02152137 2025-01-27
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT06235216 2024-11-01
SETHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Recruiting
NCT03565536 2024-04-19
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Fujian Medical University
Phase 2 Completed
NCT06362694 2024-04-12
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Saint Petersburg State University, Russia
Phase 2 Recruiting
NCT04739566 2024-03-25
ANAPLAST-NEO
Saint Petersburg State University, Russia
Phase 2 Withdrawn
NCT03488134 2024-03-19
Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3
National Taiwan University Hospital
Completed
NCT02244463 2024-01-12
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT06079333 2023-10-12
NEO-ATACT
Leiden University Medical Center
Phase 2 Recruiting
NCT04031339 2023-05-10
ITCO
University of Roma La Sapienza
Unknown
NCT05796960 2023-04-04
ATCEU
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Unknown
NCT03122496 2022-06-08
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02688608 2022-02-10
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT02862470 2021-07-06
Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients
National Taiwan University Hospital
Completed
NCT02726503 2020-06-17
HOPE
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT03211117 2020-03-25
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
Mayo Clinic
Phase 2 Completed
NCT00654238 2019-11-18
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
University of Pennsylvania
Phase 2 Completed
NCT02289144 2019-07-30
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT00804830 2018-08-28
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Region Skane
Phase 2 Terminated
NCT00416949 2018-07-18
Iodine I 131 in Treating Patients With Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Terminated
NCT00095836 2017-05-31
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Phase 2 Completed
NCT02516774 2016-01-26
TAM-RT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Withdrawn
NCT01164176 2014-12-02
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Phase 2 Completed
NCT00115739 2014-04-21
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00280852 2011-11-21
Review of Multimodality Management of Anaplastic Thyroid Cancer
AHS Cancer Control Alberta
Completed
NCT00786552 2011-01-20
Panthera
University Hospital Schleswig-Holstein
Phase 2 Unknown
NCT00060242 2010-06-11
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00077103 2010-06-11
Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
Case Comprehensive Cancer Center
Phase 1/2 Terminated
NCT00005647 2010-06-10
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Case Comprehensive Cancer Center
Phase 1 Completed